drugset / Trial / NCT05633979
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find a recommended dose of valemetostat that can be given in combination with trastuzumab deruxtecan to patients with low/ultra-low HER2-expressing metastatic breast cancer.
Timeline
- Start
- 2023-02-09
- Primary completion
- 2030-12-31
- Completion
- 2032-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | — | Intravenous |
| Subject | Valemetostat | Small molecule | — | Oral |